Which has stronger earnings and valuation, FBRX or OKUR?

Forte Biosciences is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.64 N/A OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A

Is FBRX or OKUR more profitable?

OnKure Therapeutics' return on equity of -61.02% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -106.17% -85.50% OnKure Therapeutics N/A -61.02% -55.99%

Does the media prefer FBRX or OKUR?

In the previous week, Forte Biosciences had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 11 mentions for Forte Biosciences and 7 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.20 beat Forte Biosciences' score of 0.63 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OnKure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer OKUR or SPRY?

In the previous week, OnKure Therapeutics and OnKure Therapeutics both had 7 articles in the media. OnKure Therapeutics' average media sentiment score of 1.20 beat ARS Pharmaceuticals' score of 0.54 indicating that OnKure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger earnings and valuation, OKUR or TECX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is OKUR or TECX more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -61.02% -55.99% Tectonic Therapeutic N/A -32.33% -30.92%

Does the media favor OKUR or TECX?

In the previous week, OnKure Therapeutics had 4 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 7 mentions for OnKure Therapeutics and 3 mentions for Tectonic Therapeutic. OnKure Therapeutics' average media sentiment score of 1.20 beat Tectonic Therapeutic's score of 0.19 indicating that OnKure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, OKUR or ALLO?

Allogene Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A Allogene Therapeutics N/A N/A -$190.89M -$0.77 N/A

Is OKUR or ALLO more profitable?

Allogene Therapeutics' return on equity of -56.45% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -61.02% -55.99% Allogene Therapeutics N/A -56.45% -40.36%

Does the media favor OKUR or ALLO?

In the previous week, OnKure Therapeutics had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for OnKure Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.56 beat OnKure Therapeutics' score of 1.20 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

OnKure Therapeutics (OKUR) Competitors

$4.12 -0.10 (-2.37%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$4.14 +0.01 (+0.36%)

As of 07/24/2026 07:34 PM Eastern

Compare

OKUR vs. FBRX, GYRE, SPRY, TECX, and ALLO

Should you buy OnKure Therapeutics stock or one of its competitors? MarketBeat compares OnKure Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OnKure Therapeutics include Forte Biosciences (FBRX), Gyre Therapeutics (GYRE), ARS Pharmaceuticals (SPRY), Tectonic Therapeutic (TECX), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry.

How does OnKure Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, Forte Biosciences had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 11 mentions for Forte Biosciences and 7 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.20 beat Forte Biosciences' score of 0.63 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OnKure Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Forte Biosciences is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Forte Biosciences presently has a consensus target price of $68.75, indicating a potential upside of 25.50%. OnKure Therapeutics has a consensus target price of $21.00, indicating a potential upside of 409.71%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OnKure Therapeutics' return on equity of -61.02% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-106.17%	-85.50%
OnKure Therapeutics	N/A	-61.02%	-55.99%

Forte Biosciences has a beta of 2.85, suggesting that its share price is 185% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

OnKure Therapeutics beats Forte Biosciences on 8 of the 13 factors compared between the two stocks.

How does OnKure Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Gyre Therapeutics has higher revenue and earnings than OnKure Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	5.68	$5.03M	-$0.09	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

OnKure Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
OnKure Therapeutics	N/A	-61.02%	-55.99%

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, OnKure Therapeutics had 6 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for OnKure Therapeutics and 1 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.87 beat OnKure Therapeutics' score of 1.20 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
OnKure Therapeutics	Positive

Gyre Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Gyre Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 186.20%. OnKure Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 409.71%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Gyre Therapeutics beats OnKure Therapeutics on 10 of the 15 factors compared between the two stocks.

How does OnKure Therapeutics compare to ARS Pharmaceuticals?

OnKure Therapeutics (NASDAQ:OKUR) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

OnKure Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. OnKure Therapeutics' return on equity of -61.02% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

OnKure Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 409.71%. ARS Pharmaceuticals has a consensus target price of $28.20, indicating a potential upside of 374.75%. Given OnKure Therapeutics' higher possible upside, equities analysts clearly believe OnKure Therapeutics is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, OnKure Therapeutics and OnKure Therapeutics both had 7 articles in the media. OnKure Therapeutics' average media sentiment score of 1.20 beat ARS Pharmaceuticals' score of 0.54 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 2.2% of OnKure Therapeutics shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OnKure Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

OnKure Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
ARS Pharmaceuticals	$98.99M	5.96	-$171.30M	-$2.01	N/A

Summary

OnKure Therapeutics beats ARS Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does OnKure Therapeutics compare to Tectonic Therapeutic?

OnKure Therapeutics (NASDAQ:OKUR) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

In the previous week, OnKure Therapeutics had 4 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 7 mentions for OnKure Therapeutics and 3 mentions for Tectonic Therapeutic. OnKure Therapeutics' average media sentiment score of 1.20 beat Tectonic Therapeutic's score of 0.19 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 2.2% of OnKure Therapeutics shares are held by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

OnKure Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 409.71%. Tectonic Therapeutic has a consensus price target of $79.40, indicating a potential upside of 161.44%. Given OnKure Therapeutics' higher probable upside, equities research analysts clearly believe OnKure Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

OnKure Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.21, meaning that its stock price is 221% more volatile than the broader market.

Tectonic Therapeutic's return on equity of -32.33% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Summary

OnKure Therapeutics and Tectonic Therapeutic tied by winning 7 of the 14 factors compared between the two stocks.

How does OnKure Therapeutics compare to Allogene Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

In the previous week, OnKure Therapeutics had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for OnKure Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.56 beat OnKure Therapeutics' score of 1.20 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Allogene Therapeutics' return on equity of -56.45% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Allogene Therapeutics	N/A	-56.45%	-40.36%

OnKure Therapeutics currently has a consensus target price of $21.00, indicating a potential upside of 409.71%. Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 389.78%. Given OnKure Therapeutics' higher probable upside, research analysts plainly believe OnKure Therapeutics is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Allogene Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

OnKure Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Summary

Allogene Therapeutics beats OnKure Therapeutics on 9 of the 14 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKUR vs. The Competition

Export

Metric	OnKure Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$170.47M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.95	21.29	27.11	23.64
Price / Sales	N/A	160.31	512.89	89.27
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.00	7.88	10.28	6.07
Net Income	-$59.52M	$23.86M	$3.60B	$331.99M
7 Day Performance	-1.90%	-3.82%	-1.27%	-0.63%
1 Month Performance	-2.37%	-2.61%	-0.37%	-2.00%
1 Year Performance	78.35%	32.79%	18.30%	13.62%

OnKure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKUR OnKure Therapeutics	3.0171 of 5 stars	$4.12 -2.4%	$21.00 +409.7%	+73.8%	$170.47M	N/A	N/A	N/A	News Coverage Positive News Analyst Revision
FBRX Forte Biosciences	2.3831 of 5 stars	$50.73 +6.8%	$68.75 +35.5%	+409.6%	$659.45M	N/A	N/A	5	News Coverage Analyst Forecast
GYRE Gyre Therapeutics	2.4811 of 5 stars	$6.06 +3.1%	$17.00 +180.5%	-19.5%	$655.55M	$116.59M	N/A	40
SPRY ARS Pharmaceuticals	2.2911 of 5 stars	$6.36 -1.2%	$28.20 +343.4%	-66.9%	$639.51M	$84.28M	N/A	90	High Trading Volume
TECX Tectonic Therapeutic	3.2959 of 5 stars	$32.80 +2.3%	$79.40 +142.1%	+36.3%	$618.90M	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKUR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OnKure Therapeutics (OKUR) Competitors

OKUR vs. FBRX, GYRE, SPRY, TECX, and ALLO

How does OnKure Therapeutics compare to Forte Biosciences?

Summary

How does OnKure Therapeutics compare to Gyre Therapeutics?

Summary

How does OnKure Therapeutics compare to ARS Pharmaceuticals?

Summary

How does OnKure Therapeutics compare to Tectonic Therapeutic?

Summary

How does OnKure Therapeutics compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OnKure Therapeutics (OKUR) Competitors

OKUR vs. FBRX, GYRE, SPRY, TECX, and ALLO

How does OnKure Therapeutics compare to Forte Biosciences?

Does the media prefer FBRX or OKUR?

Which has stronger earnings and valuation, FBRX or OKUR?

Do insiders & institutionals hold more shares of FBRX or OKUR?

Do analysts recommend FBRX or OKUR?

Is FBRX or OKUR more profitable?

Which has more risk & volatility, FBRX or OKUR?

Summary

How does OnKure Therapeutics compare to Gyre Therapeutics?

Which has stronger valuation and earnings, GYRE or OKUR?

Is GYRE or OKUR more profitable?

Do institutionals and insiders have more ownership in GYRE or OKUR?

Does the media refer more to GYRE or OKUR?

Which has more risk and volatility, GYRE or OKUR?

Do analysts recommend GYRE or OKUR?

Summary

How does OnKure Therapeutics compare to ARS Pharmaceuticals?

Is OKUR or SPRY more profitable?

Do analysts recommend OKUR or SPRY?

Does the media prefer OKUR or SPRY?

Do institutionals & insiders hold more shares of OKUR or SPRY?

Which has more volatility and risk, OKUR or SPRY?

Which has higher valuation & earnings, OKUR or SPRY?

Summary

How does OnKure Therapeutics compare to Tectonic Therapeutic?

Does the media favor OKUR or TECX?

Do insiders & institutionals hold more shares of OKUR or TECX?

Do analysts prefer OKUR or TECX?

Which has stronger earnings and valuation, OKUR or TECX?

Which has more risk & volatility, OKUR or TECX?

Is OKUR or TECX more profitable?

Summary

How does OnKure Therapeutics compare to Allogene Therapeutics?

Does the media favor OKUR or ALLO?

Is OKUR or ALLO more profitable?

Do analysts prefer OKUR or ALLO?

Do insiders and institutionals hold more shares of OKUR or ALLO?

Which has better valuation and earnings, OKUR or ALLO?

Which has more volatility & risk, OKUR or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools